Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.78−0.08 (-2.80%)
Close on Nov 13, 2026Market cap $152.26MP/E –Yield –
Upstream Bio r&d expenses
Research and development expenses are spending on new products and technology.
Upstream Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $149.43M, up 26.2% year over year. For fiscal 2025 it was $136.81M, up 117.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.81M | +117.3% |
| FY2024 | Dec 31, 2024 | $62.97M | +98.0% |
| FY2023 | Dec 31, 2023 | $31.80M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $36.61M | +11.0% |
| Q2 FY2026 | Jun 30, 2026 | $36.09M | -4.7% |
| Q1 FY2026 | Mar 31, 2026 | $36.57M | +41.7% |
| Q4 FY2025 | Dec 31, 2025 | $40.17M | +84.5% |
| Q3 FY2025 | Sep 30, 2025 | $32.98M | +113.7% |
| Q2 FY2025 | Jun 30, 2025 | $37.87M | +169.1% |
| Q1 FY2025 | Mar 31, 2025 | $25.80M | +120.7% |
| Q4 FY2024 | Dec 31, 2024 | $21.77M | +88.4% |
| Q3 FY2024 | Sep 30, 2024 | $15.43M | +98.2% |
| Q2 FY2024 | Jun 30, 2024 | $14.07M | – |
| Q1 FY2024 | Mar 31, 2024 | $11.69M | – |
| Q4 FY2023 | Dec 31, 2023 | $11.55M | – |
| Q3 FY2023 | Sep 30, 2023 | $7.79M | – |
See a number that looks wrong?